مراجعة
[Immunotherapy in multiple myeloma].
| العنوان: | [Immunotherapy in multiple myeloma]. |
|---|---|
| المؤلفون: | Asensi Cantó, Pedro, Arnao Herraiz, Mario, de la Rubia Comos, Javier |
| المصدر: | Med Clin (Barc) ; ISSN:1578-8989 ; Volume:162 ; Issue:10 |
| بيانات النشر: | Elsevier Science |
| سنة النشر: | 2024 |
| المجموعة: | PubMed Central (PMC) |
| مصطلحات موضوعية: | Anticuerpo biespecífico, Bispecific antibody, CAR-T cells, Células CAR-T, Immunotherapy, Inmunoterapia, Mieloma múltiple, Multiple myeloma |
| الوصف: | Patients with multiple myeloma who present with refractory disease or relapse after receiving the main classes of available drugs -immunomodulators, proteasome inhibitors and antibodies against CD38- do not have satisfactory therapeutic alternatives. New treatments based on the redirection of T lymphocytes to act directly against tumor cells, such as bispecific antibodies and T cells with chimeric antigen receptors, are changing this scenario. The published information confirms unprecedented antitumor activity of these agents in patients with refractory myeloma and they will certainly represent the backbone of the treatment of these patients in the immediate future. However, these therapies also present specific characteristics and medium or long-term toxicities that pose new healthcare challenges. In this review, we address the current results and future challenges of the administration of these treatments in patients with relapsed or refractory multiple myeloma. |
| نوع الوثيقة: | review article in journal/newspaper |
| اللغة: | English |
| العلاقة: | https://doi.org/10.1016/j.medcli.2023.11.019Test; https://pubmed.ncbi.nlm.nih.gov/38218655Test |
| DOI: | 10.1016/j.medcli.2023.11.019 |
| الإتاحة: | https://doi.org/10.1016/j.medcli.2023.11.019Test https://pubmed.ncbi.nlm.nih.gov/38218655Test |
| حقوق: | Copyright © 2023 Elsevier España, S.L.U. All rights reserved. |
| رقم الانضمام: | edsbas.40FDF8AC |
| قاعدة البيانات: | BASE |
| DOI: | 10.1016/j.medcli.2023.11.019 |
|---|